`Filed: April 12, 2022
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________________________
`
`MYLAN PHARMACEUTICALS, INC., CELLTRION, INC., and
`APOTEX, INC.,
`Petitioners,
`
`v.
`
`REGENERON PHARMACEUTICALS, INC.,
`Patent Owner.
`
`_____________________________
`
`IPR2021-008811
`Patent No. 9,254,338
`
`_____________________________
`
`PETITIONER UPDATED EXHIBIT LIST
`
`1 IPR2022-00258 has been joined with this proceeding.
`
`
`
`Exhibit
`
`No.
`
`Description
`
`1001
`
`U.S. Patent No. 9,254,338 B2 (“’338 patent”)
`
`1002
`
`Expert Declaration of Dr. Thomas A. Albini in Support of Petition for
`
`Inter Partes Review of Patent No. 9,254,338 B2, dated May 4, 2021
`
`(“Albini”)
`
`1003
`
`Expert Declaration of Mary Gerritsen, Ph.D. in Support of Petition
`
`for Inter Partes Review of U.S. Patent No. 9,254,338 B2, dated Apr.
`
`26, 2021 (“Gerritsen”)
`
`1004
`
`1005
`
`1006
`
`1007
`
`Jocelyn Holash et al., VEGF-Trap: A VEGF Blocker with Potent
`Antitumor Effects, 99 PROC. NAT’L ACAD. SCI. 11393 (2002)
`(“Holash”)
`
`Quan Dong Nguyen et al., A Phase I Study of Intravitreal Vascular
`Endothelial Growth Factor Trap-Eye in Patients with Neovascular
`Age-Related Macular Degeneration, 116 OPHTHALMOLOGY 2141
`(2009) (“Nguyen-2009”)
`
`James A Dixon et al., VEGF Trap-Eye for the Treatment of
`Neovascular Age-Related Macular Degeneration, 18 EXPERT
`OPINION ON INVESTIGATIONAL DRUGS 1573 (2009) (“Dixon”)
`
`Adis R&D Profile, Aflibercept: AVE 0005, AVE 005, AVE0005,
`VEGF Trap – Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye, 9
`DRUGS R&D 261 (2008) (“Adis”)
`
`1008
`
`U.S. Patent No. 7,531,173 B2 (“’173 patent”)
`
`-2-
`
`
`
`1009
`
`U.S. Patent No. 7,396,664 B2 (“’664 patent”)
`
`1010
`
`U.S. Patent No. 7,374,758 B2 (“’758 patent”)
`
`1011
`
`1012
`
`1013
`
`1014
`
`F Semeraro et al., Aflibercept in Wet AMD: Specific Role and
`Optimal Use, 7 DRUG DESIGN, DEV. & THERAPY 711 (2013)
`(“Semeraro”)
`
`Press Release, Regeneron, Regeneron and Bayer Health Care
`Announce Encouraging 32-Week Follow-Up Results from a Phase 2
`Study of VEGF Trap-Eye in Age-Related Macular Degeneration
`(Apr. 28, 2008),
`http://investor.regeneron.com/releasedetail.cfm?releaseid=394066
`(“Regeneron (28-April-2008)”)
`
`Press Release, Regeneron, Bayer and Regeneron Dose First Patient
`in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related
`Macular Degeneration (May 8, 2008),
`http://investor.regeneron.com/releasedetail.cfm?ReleaseID=394065
`(“Regeneron (8-May-2008)”)
`
`Vascular Endothelial Growth Factor (VEGF) Trap-Eye:
`Investigation of Efficacy and Safety in Wet Age-Related Macular
`Degeneration (AMD) (VIEW1), NCT00509795,
`ClinicalTrials.gov (Apr. 28, 2009),
`https://clinicaltrials.gov/ct2/show/NCT00509795 (“NCT-795”)
`
`1015
`
`VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD
`(VIEW 2), NCT00637377, ClinicalTrials.gov (Mar. 17, 2008),
`https://clinicaltrials.gov/ct2/show/NCT00637377 (“NCT-377”)
`
`1016
`
`U.S. Patent Nos. 7,303,746 B2; 7,303,747 B2; 7,306,799 B2; and
`7,521,049 B2 (“Monthly-Dosing-Patents”)
`
`1017
`
`File History of U.S. Patent No. 9,254,338 B2 (“’338 FH”)
`
`1018
`
`Jeffrey S. Heier et al., Intravitreal Aflibercept (VEGF Trap-Eye) in
`Wet Age-Related Macular Degeneration, 119 OPHTHALMOLOGY
`
`-3-
`
`
`
`2537 (2012) (“Heier-2012”)
`
`1019
`
`U.S. Patent No. 9,669,069 B2 (“’069 patent”)
`
`1020
`
`Jeffrey S. Heier, Intravitreal VEGF Trap for AMD: An Update,
`
`RETINA TODAY, Oct. 2009, 44 (“Heier-2009”)
`
`1021
`
`Regeneron Pharm., Inc., Quarterly Report (Form 10-Q) (Sept. 30,
`
`2009) (“2009 10-Q”)
`
`1022
`
`U.S. Patent No. 7,374,757 B2 (“’757 patent”)
`
`1023
`
`U.S. Patent No. 7,070,959 B1 (“’959 patent”)
`
`1024
`
`File History of U.S. Patent No. 7,374,758 B2, 12/22/2011 Patent
`
`Term Extension Application (“’758 FH, 12/22/2011 PTE”)
`
`1025 Michael Engelbert et al., Long-Term Follow-Up For Type 1
`(Subretinal Pigment Epithelium) Neovascularization Using A
`Modified “Treat And Extend” Dosing Regimen of Intravitreal
`Antivascular Endothelial Growth Factor Therapy, 30 RETINA, J.
`RETINAL & VITREOUS DISEASES 1368 (2010) (“Engelbert-2010”)
`
`1026 Michael Engelbert et al., “Treat and Extend” Dosing of Intravitreal
`Antivascular Endothelial Growth Factor Therapy For Type 3
`Neovascularization/Retinal Angiomatous Proliferation, 29 J.
`RETINAL & VITREOUS DISEASES 1424 (2009) (“Engelbert-2009”)
`
`1027
`
`Richard F. Spaide et al., Prospective Study of Intravitreal
`
`Ranibizumab as a Treatment for Decreased Visual Acuity Secondary
`
`-4-
`
`
`
`to Central Retinal Vein Occlusion, 147 AM. J. OPHTHALMOLOGY 298
`
`(2009) (“Spaide”)
`
`1028
`
`1029
`
`1030
`
`Press Release, Regeneron, Bayer and Regeneron Extend
`Development Program for VEGF Trap-Eye to Include Central
`Retinal Vein Occlusion (Apr. 30, 2009),
`https://investor.regeneron.com/news-releases/news-release-
`details/bayer-and-regeneron-extend-development-program-
`vegf- trap-eye (“Regeneron (30-April-2009)”)
`
`Vascular Endothelial Growth Factor (VEGF) Trap-Eye:
`Investigation of Efficacy and Safety in Central Retinal Vein
`Occlusion (CRVO), NCT01012973, ClinicalTrials.gov (Nov. 12,
`2009), https://clinicaltrials.gov/ct2/show/NCT01012973 (“NCT-
`973”)
`
`P Mitchell et al., Ranibizumab (Lucentis) in Neovascular Age-
`Related Macular Degeneration: Evidence from Clinical Trials, 94
`BRIT. J. OPHTHALMOLOGY 2 (2009) (date of online publication)
`(“Mitchell”)
`
`1031
`
`Pascale G. Massin, Anti-VEGF Therapy for Diabetic Macular
`
`Edema: An Update, RETINA TODAY, SEPT./Oct. 2008, 54 (“Massin”)
`
`1032
`
`Press Release, Bayer AG, Bayer and Regeneron Start Additional
`Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular
`Degeneration (May 8, 2008) (“Bayer (8-May-2008)”)
`
`1033
`
`U.S. Patent Application Publication No. 2006/0217311 A1 (“Dix”)
`
`-5-
`
`
`
`1034
`
`1035
`
`1036
`
`1037
`
`Anne E. Fung et al., An Optical Coherence Tomography-Guided,
`Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis)
`for Neovascular Age-related Macular Degeneration, 143 AM. J.
`OPHTHALMOLOGY 566 (2007) (“Fung”)
`
`Geeta A. Lalwani et al., A Variable-dosing Regimen with
`Intravitreal Ranibizumab for Neovascular Age-Related Macular
`Degeneration: Year 2 of the PrONTO Study, 148 AM. J.
`OPHTHALMOLOGY 43 (2009) (“Lalwani”)
`
`Peter A Campochiaro et al., Ranibizumab for Macular Edema Due
`to Retinal Vein Occlusions: Implication of VEGF as a Critical
`Stimulator, 16 MOLECULAR THERAPY 791 (2008) (“Campochiaro”)
`
`Robert Steinbrook, The Price of Sight — Ranibizumab, Bevacizumab,
`and the Treatment of Macular Degeneration, 355 N. ENG. J. MED.
`1409 (2006) (“Steinbrook”)
`
`1038
`
`Curriculum Vitae of Dr. Thomas Albini (“Albini CV”)
`
`1039
`
`U.S. Patent No. 7,378,095 B2 (“’095 patent”)
`
`1040
`
`1041
`
`1042
`
`International Nonproprietary Names for Pharmaceutical
`Substances (INN), 20 WHO DRUG INFORMATION 115 (2006)
`(“WHO Drug Info”)
`
`Press Release, Regeneron, Regeneron Reports Full Year and Fourth
`Quarter 2008 Financial and Operating Results (Feb. 26, 2009),
`https://investor.regeneron.com/news-releases/news-release-
`details/regeneron-reports-full-year-and-fourth-quarter-2008-
`financial (“Regeneron (26-February-2009)”)
`
`U.S. DEP’T HEALTH & HUMAN SERVS., NAT’L INST. HEALTH, NAT’L
`EYE INST., Age-Related Macular Degeneration: What You Should
`Know (Sept. 2015),
`https://www.nei.nih.gov/sites/default/files/health-pdfs/WYSK
`AMD English Sept2015 PRINT.pdf (“NIH AMD”)
`
`-6-
`
`
`
`1043
`
`1044
`
`1045
`
`1046
`
`1047
`
`David M. Brown & Carl D. Regillo, Anti-VEGF Agents in the
`Treatment of Neovascular Age-Related Macular Degeneration:
`Applying Clinical Trial Results to the Treatment of Everyday
`Patients, 144 AM. J. OPHTHALMOLOGY 627 (2007) (“Brown”)
`
`U.S. DEP’T HEALTH & HUMAN SERVS., NAT’L INST. HEALTH, NAT’L
`EYE INST., Diabetic Retinopathy: What You Should Know (Sept.
`2015), https://www.nei.nih.gov/sites/default/files/2019-06/Diabetic-
`Retinopathy-What-You-Should-Know-508.pdf (“NIH DR”)
`
`Napoleone Ferrara & Kari Alitalo, Clinical Applications of
`Angiogenic Growth Factors and Their Inhibitors, 5 NATURE MED.
`1359 (1999) (“Ferrara-1999”)
`
`Napoleone Ferrara & Robert S. Kerbel, Angiogenesis as a
`Therapeutic Target, 438 NATURE 967 (2005) (“Ferrara-2005”)
`
`Ziad F. Bashshur et al., Intravitreal Bevacizumab for the
`Management of Choroidal Neovascularization in Age-Related
`Macular Degeneration, 142 AM. J. OPHTHALMOLOGY 1 (2006)
`(“Bashshur”)
`
`1048
`
`LUCENTIS® Prescribing Information (2006) (“Lucentis”)
`
`1049
`
`L. Spielberg & A. Leys, Intravitreal Bevacizumab for Myopic
`Choroidal Neovascularization: Short-Term and 1-Year Results, 312
`BULLETIN SOCIETE BELGE D’OPHTALMOLOGIE 17 (2009)
`(“Spielberg”)
`
`1050
`
`Ursula Schmidt-Erfurth, Current Concepts in the Management of
`
`Diabetic Macular Edema, 7 PROCEEDINGS 52 (2010) (“Schmidt-
`
`Erfurth”)
`
`1051
`
`Pearse A. Keane et al., Effect of Ranibizumab Retreatment Frequency
`on Neurosensory Retinal Volume in Neovascular AMD, 29 RETINA
`592 (2009) (“Keane”)
`
`-7-
`
`
`
`1052
`
`1053
`
`1054
`
`1055
`
`1056
`
`1057
`
`J.S. Rudge et al., VEGF Trap as a Novel Antiangiogenic Treatment
`Currently in Clinical Trials for Cancer and Eye Diseases, and
`VelociGene®-Based Discovery of the Next Generation of
`Angiogenesis Targets, 70 COLD SPRING HARBOR SYMPOSIA
`QUANTITATIVE BIOLOGY 411 (2005) (“Rudge”)
`
`Press Release, Regeneron, Positive Interim Phase 2 Data
`Reported for VEGF Trap-Eye in Age-Related Macular
`Degeneration (Mar. 27, 2007),
`https://newsroom.regeneron.com/news-releases/news- release-
`details/positive-interim-phase-2-data-reported-vegf-trap-eye-age-
`related?releaseid=394105 (“Regeneron (27-March-2007)”)
`
`Press Release, Regeneron, Regeneron and Bayer Healthcare
`Initiate Phase 3 Global Development Program for VEGF Trap-Eye
`in Wet Age-Related Macular Degeneration (AMD) (Aug. 2,
`2007), https://investor.regeneron.com/news-releases/news-release-
`details/regeneron-and-bayer-healthcare-initiate-phase-3-global
`(“Regeneron (2-August-2007)”)
`
`Retina Society, VEGF Trap-Eye in Wet AMD CLEAR-IT 2:
`Summary of One-Year Key Results, A Phase 2, Randomized,
`Controlled Dose-and Interval-Ranging Study of Intravitreal VEGF
`Trap-Eye in Patients With Neovascular, Age-Related Macular
`Degeneration (Sept. 28, 2008) (“Retina Society Meeting
`Presentation”)
`
`Press Release, Regeneron, VEGF Trap-Eye Final Phase 2 Results in
`Age-related Macular Degeneration Presented at 2008 Retina Society
`Meeting (Sept. 28, 2008), https://investor.regeneron.com/news-
`releases/news-release-details/vegf-trap-eye-final-phase-2-results-
`age-related-macular?ReleaseID=393906 (“Regeneron (28-
`September-2008)”)
`
`Press Release, Regeneron, VEGF Trap-Eye Shows Positive Results
`in a Phase 2 Study in Patients with Diabetic Macular Edema (Feb.
`18, 2010), https://investor.regeneron.com/news-releases/news-
`release-details/vegf-trap-eye-shows-positive-results-phase-2-study-
`patients?releaseid=445521 (“Regeneron (18-February-2010)”)
`
`-8-
`
`
`
`1058
`
`1059
`
`1060
`
`ASS’N FOR RES. VISION & OPHTHALMOLOGY, ARVO® News
`(Winter/Spring 2008) (“ARVONews Winter/Spring 2008”)
`
`ASS’N FOR RES. VISION & OPHTHALMOLOGY, ARVO® News
`(Summer 2007) (“ARVONews Summer 2007”)
`
`Jean-François Korobelnik et al., Intravitreal Aflibercept Injection for
`Macular Edema Resulting from Central Retinal Vein Occlusion, 121
`OPHTHALMOLOGY 202 (2014) (“Korobelnik”)
`
`1061
`
`Curriculum Vitae of Dr. Mary Gerritsen (“Gerritsen CV”)
`
`1062
`
`EP 2 663 325 (published as WO 2012/097019 A1) (“EP-325”)
`
`1063
`
`File History of EP 2 663 325 (“EP-325-FH”)
`
`1064
`
`1065
`
`1066
`
`1067
`
`1068
`
`BMJ Publishing Group Ltd., Online First, BJO ONLINE, (Feb. 11,
`2009), https://bjo.bmj.com/onlinefirst.dtl
`[http://web.archive.org/web/20090212162702/https://bjo.bmj.com/o
`nlinefirst.dtl] (“Wayback-BJO-Online First”)
`
`BMJ Publishing Group Ltd., Review: Ranibizumab (Lucentis) In
`Neovascular Age-Related Macular Degeneration: Evidence From
`Clinical Trials, BRITISH J. OPHTHALMOLOGY (Dec. 2020),
`https://bjo.bmj.com/content/94/1/2.altmetrics (“BJO-Article
`Metrics”)
`
`Press Release, Bayer, VEGF Trap-Eye Shows Positive Results in
`Phase II Study in Patients with Diabetic Macular Edema (Feb. 18,
`2010) (“Bayer (18-February-2010)”)
`
`Press Release, Bayer, Bayer Health Care and Regeneron Announce
`Encouraging 32-Week Follow Up Results From A Phase 2 Study of
`VEGF Trap-Eye in Age-Related Macular Degeneration (Apr. 28,
`2008) (“Bayer (28-April-2008)”)
`
`Press Release, Regeneron, Enrollment Completed in Regeneron
`and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in
`Neovascular Age-Related Macular Degeneration (Wet AMD)
`-9-
`
`
`
`1069
`
`1070
`
`(Sept. 14, 2009), https://investor.regeneron.com/news-
`releases/news- release-details/enrollment-completed-regeneron-
`and-bayer- healthcare-phase-3?ReleaseID=408872 (“Regeneron
`(14-September-2009)”)
`
`ClinicalTrials.gov, What Is ClinicalTrials.gov?, U.S. NAT’L LIBRARY
`MED. (Jan. 2018), https://www.clinicaltrials.gov/ct2/about-
`site/background (“Background-ClinicalTrials.gov”)
`
`Affidavit of Duncan Hall (Internet Archive Records Request
`Processor) Regarding Vascular Endothelial Growth Factor (VEGF)
`Trap-Eye: Investigation of Efficacy and Safety in Central Retinal
`Vein Occlusion (CRVO) (GALILEO), NCT01012973,
`ClinicalTrials.gov (Apr. 8, 2011); Vascular Endothelial Growth
`Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in
`Wet Age-Related Macular Degeneration (AMD) (VIEW1),
`NCT00509795, ClinicalTrials.gov (Apr. 8, 2011); and VEGF Trap-
`Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW 2),
`NCT00637377, ClinicalTrials.gov (Aug. 13, 2009), dated January
`20, 2021 (“Wayback-Affidavit-069”)
`
`1071
`
`Frank G Holz et al., VEGF Trap-Eye for Macular Oedema
`Secondary to Central Retinal Vein Occlusion: 6-Month Results of
`the Phase III GALILEO Study, 97 BRITISH J. OPHTHALMOLOGY 278
`(2013) (“Holz”)
`
`1072
`
`Janice M. Reichert, Antibody-Based Therapeutics To Watch In 2011,
`
`3 MABS 76 (2011) (“Reichert”)
`
`1073
`
`Owen A. Anderson et al., Delivery of Anti-Angiogenic Molecular
`Therapies for Retinal Disease, 15 DRUG DISCOVERY TODAY 272
`(2010) (“Anderson”)
`
`-10-
`
`
`
`1074
`
`1075
`
`1076
`
`1077
`
`Thomas A. Ciulla & Philip J. Rosenfeld, Antivascular Endothelial
`Growth Factor Therapy For Neovascular Age-Related Macular
`Degeneration, 20 CURRENT OPINION OPHTHALMOLOGY 158 (2009)
`(“Ciulla”)
`
`Zhang Ni & Peng Hui, Emerging Pharmacologic Therapies for Wet
`Age-Related Macular Degeneration, 223 OPHTHALMOLOGICA 401
`(2009) (“Ni”)
`
`Marco A. Zarbin & Philip J. Rosenfeld, Pathway-Based
`Therapies for Age-Related Macular Degeneration: An Integrated
`Survey of Emerging Treatment Alternatives, 30 RETINA 1350
`(2010) (“Zarbin”)
`
`Corporate Finance Institute, SEC Filings: Public Disclosures About
`Public Companies,
`https://corporatefinanceinstitute.com/resources/data/public-
`filings/sec-filings/ (last visited May 5, 2021) (“Corporate Finance
`Institute”)
`
`1078
`
`Carl W. Schneider, Nits, Grits, and Soft Information in SEC Filings,
`
`121 U. PA. L. REV. 254 (1972) (“Schneider”)
`
`1079
`
`Justin Kuepper, The Best Investment Information Sources: Using
`SEC Filings, Analyst Reports, and Company Websites, BALANCE
`(Jan. 13, 2021), https://www.thebalance.com/top-best-sources-of-
`investor-information-1979207 (“Kuepper”)
`
`1080
`
`Kristina Zucchi, EDGAR: Investors’ One-Stop-Shop For Company
`
`Filings, YAHOO!LIFE (Jan. 31, 2014),
`
`https://www.yahoo.com/lifestyle/tagged/health/edgar-investors-one-
`
`stop-shop-170000800.html (“Zucchi”)
`
`1081
`
`Adam Hayes, SEC Filings: Forms You Need To Know,
`INVESTOPEDIA (Jan. 18, 2021),
`-11-
`
`
`
`https://www.investopedia.com/articles/fundamental-analysis/08/sec-
`forms.asp (“Hayes”)
`
`1082
`
`Amino acid sequence alignment of SEQ ID NO:2 of the ’069 patent
`
`with SEQ ID NO:16 of the ’758 patent and SEQ ID NO:4 of Dix
`
`(“’069 Amino Acid Sequences”)
`
`1083
`
`Nucleotide sequence alignment of SEQ ID NO:1 of the ’069 patent
`with SEQ ID NO:15 of the ’758 patent and SEQ ID NO:3 of Dix
`(“’069 Nucleotide Sequences”)
`
`1084
`
`U.S. Patent Application Publication No. 2006/0172944 A1
`(“Wiegand”)
`
`1085
`
`U.S. Patent Application Publication No. 2007/0190058 A1 (“Shams”)
`
`1086
`
`1087
`
`1088
`
`1089
`
`ClinicalTrials.gov, 1997: Congress Passes Law (FDAMA)
`Requiring Trial Registration, U.S. NAT’L LIBRARY MED. (Oct.
`2020), https://clinicaltrials.gov/ct2/about-site/history (“History-
`ClinicalTrials.gov”)
`
`Affidavit of Duncan Hill (Internet Archive Records Request
`Processor) Regarding Vascular Endothelial Growth Factor
`(VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet
`Age-Related Macular Degeneration (AMD) (VIEW1),
`NCT00509795, ClinicalTrials.gov (Apr. 28, 2009) and VEGF
`Trap-Eye: Investigation of Efficacy and Safety in Wet AMD
`(VIEW 2), NCT00637377, ClinicalTrials.gov (Mar. 17, 2008),
`dated January 27, 2021 (“Wayback-Affidavit-038”)
`
`Quan Dong Nguyen et al., A Phase I Trial of an IV-Administered
`Vascular Endothelial Growth Factor Trap for Treatment in Patients
`with Choroidal Neovascularization due to Age-Related Macular
`Degeneration, 113 OPHTHALMOLOGY 1522 (2006) (“Nguyen-2006”)
`
`Press Release, Regeneron, Regeneron and Bayer Healthcare
`Announce VEGF Trap-Eye Achieved Durable Improvement in
`Vision Over 52 Weeks in a Phase 2 Study in Patients with Age
`-12-
`
`
`
`Related Macular Degeneration (Aug. 19, 2008),
`https://investor.regeneron.com/news-releases/news-release-
`details/regeneron-and-bayer-healthcare-announce-vegf-trap-eye-
`achieved?ReleaseID=394056 (“Regeneron (19-August-2008)”)
`
`1090
`
`Eugene S. Kim et al., Potent VEGF Blockade Causes Regression of
`Coopted Vessels in a Model of Neuroblastoma, 99 PROC. NAT’L
`ACAD. SCI. 11399 (2002) (“Kim”)
`
`1091
`
`EYLEA® Prescribing Information (“Eylea PI”)
`
`1092
`
`1093
`
`1094
`
`1095
`
`1096
`
`1097
`
`Press Release, Bayer, Bayer HealthCare and Regeneron Announce
`VEGF Trap-Eye Achieved Durable Improvement in Vision Over 52
`Weeks in a Phase 2 Study in Patients with Age-Related Macular
`Degeneration (Aug. 19, 2008) (“Bayer (19-August-2008)”)
`
`Amino acid sequence alignment of SEQ ID NO:2 of the ’338 patent
`with SEQ ID NO:16 of the ’758 patent and SEQ ID NO:4 of Dix
`(“’338 Amino Acid Sequences”)
`
`Nucleotide sequence alignment of SEQ ID NO:1 of the ’338 patent
`with SEQ ID NO:15 of the ’758 patent and SEQ ID NO:3 of Dix
`(“’338 Nucleotide Sequences”)
`
`Declaration of Robert V. Cerwinski in Support of Motion for Pro
`Hac Vice Admission
`
`Declaration of Aviv A. Zalcenstein in Support of Motion for Pro Hac
`Vice Admission
`
`Declaration of Brigid M. Morris in Support of Motion for Pro Hac
`Vice Admission
`
`Dated: April 12, 2022
`
`
`
`Respectfully submitted,
`
`/Lora M. Green/
`
` Lora M. Green, Lead Counsel
` Reg. No. 43,541
`
`-13-
`
`
`
`CERTIFICATE OF SERVICE
`This is to certify that I caused to be served true and correct copy of the
`
`foregoing Updated Exhibit List and EX1095-EX1097 on this 12th day of April 2022,
`
`on the Patent Owner at the correspondence address of the Patent Owner as follows:
`
`Deborah Fishman
`
`Deborah.fishman@arnoldporter.com
`
`David Cain
`
`David.Caine@arnoldporter.com
`
`Alice Sin Yu Ho
`
`Alice.ho@arnoldporter.com
`
`Victoria Reines
`
`Victoria.Reines@arnoldporter.com
`
`Jeremy Cobb
`
`Jeremy.Cobb@arnoldporter.com
`
`Daniel Reisner
`
`Daniel.Reisner@arnoldporter.com
`
`Matthew Wilk
`
`Matthew.Wilk@arnoldporter.com
`
`RegeneronEyleaIPRs@arnoldporter.com
`
`And to Counsel for Petitioner Mylan Pharmaceuticals in IPR2021-00881, as follows:
`
`Paul Molino
`
`paul@rmmslegal.com
`
`William A. Rakoczy
`
`wrakoczy@rmmslegal.com
`
`Heinz Salmen
`
`hsalmen@rmmslegal.com
`
`-14-
`
`
`
`Neil McLaughlin
`
`Teresa Rea
`
`Deborah Yellin
`
`Shannon Lentz
`
`nmclaughlin@rmmslegal.com
`
`trea@crowell.com
`
`dyellin@crowell.com
`
`slentz@crowell.com
`
`MYL_REG_IPR@rmmslegal.com
`
`Dated: April 12, 2022
`
`
`
`Respectfully submitted,
`
`/Lora M. Green/
`
` Lora M. Green, Lead Counsel
` Reg. No. 43,541
`
`-15-
`
`